+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
ID06096909

Early Use of Tafolecimab with Lipid-Lowering Therapy for Acute Coronary Syndrome Patients Undergoing PCI in China A Randomized Controlled Trial

Led by China National Center for Cardiovascular Diseases · Updated on 2026-10-27

3684

Participants Needed

2

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying patients with acute coronary syndrome ACS who are undergoing percutaneous coronary intervention PCI. The trial evaluates the early use of tafolecimab, a PCSK9 monoclonal antibody, added to standard lipid-lowering therapy compared to conventional treatment strategies. This approach aims to lower LDL cholesterol levels quickly and reduce major adverse cardiovascular and cerebrovascular events, filling a gap where early initiation of PCSK9 antibodies during the acute phase has not yet been studied in large randomized trials. Participants are randomly assigned to one of two groups. One group receives intensive lipid-lowering therapy with tafolecimab injections every two weeks alongside statins and cholesterol absorption inhibitors, while the other group receives conventional lipid-lowering therapy with statins and cholesterol absorption inhibitors alone. The study has two stages the first 24 weeks compare the intensive versus conventional approaches, followed by a period from week 25 to week 104 where physicians adjust treatments according to local cholesterol management guidelines. During the study, participants will have regular assessments of cardiovascular health and cholesterol levels, with the main outcome measured being major adverse cardiovascular and cerebrovascular events at week 104. Secondary outcomes include events at week 26, combined outcomes with all-cause death, and lipid control outcomes. Safety monitoring and treatment adherence will be tracked throughout the study, which is expected to last until 2028. The study is conducted under double-blind conditions to ensure unbiased results.

CONDITIONS

Brief Title

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

Research Team

N

Na-Qiong Wu, Doctor

Z

Zheng Yin, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here